Neuroleptil

Quick links to important sections

Neuroleptil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neuroleptil

Property Description
Active Ingredient Acepromazine maleate
Forms Oral Solution, Tablets, Injection Solution
Pharmacological Class Neuroleptic (Major Tranquilizer), Phenothiazine Derivative
General Purpose Calming and stabilizing severe emotional states
Origin Synthetic Compound

What Type of Medicine is Neuroleptil and How is it Classified?

Neuroleptil is a prescription psychoactive agent whose active substance is Acepromazine, typically supplied as its maleate salt. It is fundamentally classified as a neuroleptic drug, a term often interchangeable with major tranquilizer, and belongs to the phenothiazine derivative family of chemical compounds. This classification establishes the medicine as one that significantly influences the central nervous system (CNS). Acepromazine is clinically recognized for its potent sedative and calming properties, confirming that the medication is specifically designed to induce tranquility and reduce agitation in patients experiencing significant distress.

Composition, Origin, and Available Forms

The medication is a single-active ingredient product containing only Acepromazine maleate, derived from a sophisticated synthetic chemical process rather than natural sources. Neuroleptil is manufactured in several distinct high-level pharmaceutical forms to allow for flexibility in its use. These forms commonly include an oral solution and tablets for ingestion, as well as an injection solution for rapid onset via routes such as intramuscular (IM) or intravenous (IV) administration. Acepromazine formulations are notable among phenothiazines for their utility in both chronic and acute sedation needs, ensuring the substance can be administered effectively according to the required speed and setting of the patient’s emotional state.

What is the General Therapeutic Purpose of this Neuroleptic?

The general therapeutic purpose of Neuroleptil stems from its core action of dampening central nervous system activity. This effect is primarily achieved through dopamine receptor antagonism, influencing brain pathways that regulate emotional response. As a major tranquilizer, its function is to calm and stabilize emotional states rather than targeting a specific physical ailment. The overall effect is to help alleviate profound anxiety, extreme restlessness, or states of severe emotional unease by reducing the patient's overall emotional intensity and agitation.

What side effects are possible with Neuroleptil?

Possible Side Effects and Safety Information: Neuroleptil (Pericyazine)

The safety profile of Neuroleptil, a phenothiazine neuroleptic, is officially documented across several categories, spanning from common expected reactions to rare but serious adverse events.

Adverse Reactions by System and Frequency

Side effects are officially classified by the body system affected. Reactions classified as common in regulatory documents include drowsiness (somnolence) and orthostatic hypotension (a drop in blood pressure upon standing). Effects on the nervous system may include extrapyramidal symptoms such as involuntary movements and muscle rigidity, and anticholinergic effects like dry mouth, blurred vision, and constipation.

Serious Adverse Reactions

Government-approved labeling highlights several serious adverse reactions. Among the most critical is Neuroleptic Malignant Syndrome (NMS), a rare, potentially fatal condition marked by high fever and severe muscle stiffness. Cardiovascular risks include QT interval prolongation, which can lead to life-threatening heart rhythm disturbances. The medicine is also associated with the risk of developing Tardive Dyskinesia (potentially irreversible involuntary movements) and Venous Thromboembolism (VTE).

Population and Exposure Constraints

The regulatory safety information notes that older adults may be more susceptible to common effects like sedation and orthostatic hypotension. Furthermore, official documents indicate that exposure during the third trimester of pregnancy may result in extrapyramidal or withdrawal symptoms in the neonate. For all patients, treatment requires attention to high-level restrictions, such as the need for blood monitoring to detect very rare, severe conditions like agranulocytosis.

Overdose and Emergency Response

Overdose of Neuroleptil (Pericyazine) is officially documented in regulatory labeling with significant manifestations primarily affecting the central nervous and cardiovascular systems. Documented signs include severe drowsiness, confusion, and loss of consciousness, which can progress to a comatose state. Other serious neurological disturbances that may occur are seizures and involuntary muscle movements known as extrapyramidal symptoms.

A critical risk highlighted in official regulatory documents is cardiovascular toxicity. This involves significant changes in heart function, including low blood pressure (hypotension) and irregularities in heart rhythm. Of particular concern is the potential for QT interval prolongation, which elevates the risk for a life-threatening heart rhythm disorder known as fatal ventricular arrhythmias.

Regulatory authorities strictly require that in the event of a suspected overdose, the individual must seek immediate medical attention or report directly to a hospital casualty department. If the affected person is exhibiting serious symptoms, such as passing out or trouble breathing, emergency services must be contacted immediately. Management detailed in official documents focuses on providing intensive symptomatic and supportive care, including continuous cardiac monitoring, as no specific antidote is officially documented.

Therapeutic Uses of Neuroleptil

Neuroleptil: Main Uses and Clinical Benefits

Neuroleptil (pericyazine) is a prescription treatment primarily used to manage certain mental and mood disorders.


Quick Facts on Neuroleptil

  • Therapeutic Domain: Mental and Mood Disorders
  • Primary Use: Management of specific psychiatric conditions
  • Clinical Goal: To aid in restoring balance to certain natural substances in the brain

Clinical Applications

The most recognized clinical use for Neuroleptil is in the management of certain psychotic conditions, such as schizophrenia. Furthermore, it is also clinically used to control specific behavioral manifestations, including impulsiveness and aggressiveness, often in association with other supportive medications. The medication is utilized to help restore the balance of certain natural substances in the central nervous system, which contributes to the observed therapeutic effects in patients with these psychiatric conditions. It is important to consult a healthcare provider for a comprehensive understanding of the appropriate applications and safety profile for this treatment.

Eligibility and Restrictions for Use

Neuroleptil (periciazine) is a prescription medication whose eligibility is strictly defined by regulatory documents based on patient conditions, age, and physiological state.

Populations For Whom Use Is Contraindicated

Contraindication Category Excluded Groups
Allergy & Intoxication Hypersensitivity to periciazine or other phenothiazines; acute intoxication with central depressant drugs (including alcohol); circulatory collapse or comatose states.
Medical Conditions Pheochromocytoma; severe liver or kidney dysfunction; history of blood dyscrasias or agranulocytosis; angle-closure glaucoma; risk of urinary retention (e.g., due to prostatic hypertrophy).
Other Children younger than 1 year (due to SIDS risk); use in association with spinal or regional anesthesia.

Eligibility and Restrictions

  • Age Rules: Use in children aged 1–3 years is not recommended. Use in older adults (geriatrics) requires caution due to increased susceptibility to side effects and an elevated risk of venous thromboembolism and cerebrovascular events.
  • Pregnancy/Lactation: Use during pregnancy is generally not recommended unless the benefit outweighs the risk; if used during the third trimester, the newborn is at risk for extrapyramidal and/or withdrawal symptoms. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Neuroleptil (periciazine) can interact with a range of medicinal products and substances due to its effects on the central nervous system (CNS) and its anticholinergic activity. These interactions may result in enhanced effects of co-administered drugs or increased risk of adverse reactions.

Key Interacting Categories and Restrictions

  • CNS Depressants and Alcohol: Concurrent use of Neuroleptil with alcohol or other CNS depressants (such as barbiturates, general anesthetics, narcotics, or certain antihistamines) can potentiate the sedative and depressant effects, leading to increased drowsiness or respiratory risk. Patients must be advised against ingesting alcohol. When co-administered with other CNS depressants, the usual doses of these compounds should be reduced by at least half.
  • Anticholinergic Drugs: Co-administration with drugs that also have anticholinergic properties may increase the risk of side effects like paralytic ileus or urinary retention, particularly in elderly patients.
  • Cardiovascular Agents: Neuroleptil can cause hypotension. If a pressor agent is required to treat low blood pressure, epinephrine should not be used as it may paradoxically cause a further drop in blood pressure. Norepinephrine or phenylephrine are preferred alternatives. Caution is also advised with other drugs likely to cause postural hypotension.
  • Other Neuroleptics/Phenothiazines: Caution is warranted when co-prescribed with other phenothiazine derivatives due to the potential for additive effects and increased risk of serious ventricular arrhythmias, including torsade de pointes, related to potential QT interval prolongation.
  • Contraindications: Use is contraindicated in states of altered consciousness or collapse, especially when due to intoxication with central depressant drugs, and in association with spinal or regional anesthesia.
  • Environmental: Increased toxicity of certain organophosphorous insecticides may occur; caution regarding exposure is recommended.

Mechanism of Action

The mechanism of action for Neuroleptil (Acepromazine) is defined by its ability to act as a multi-receptor antagonist, blocking activity across several key neurotransmitter systems in the brain and body.

Antagonism of Central Dopamine Receptors

This domain covers the drug's primary interaction with D2 dopamine receptors in the central nervous system (CNS), particularly within the limbic system. By blocking these receptors, the medication dampens excessive dopaminergic signaling, which is the molecular foundation for its CNS depression and reduction of central arousal.

Modulation of Autonomic Signaling and Vascular Tone

Acepromazine exerts a significant effect outside the CNS through antagonism of peripheral alpha1 adrenergic receptors found on blood vessel walls. This mechanistic interaction relaxes vascular smooth muscle, leading to a reduction in systemic vascular resistance and a corresponding lowering of blood pressure (hypotension), defining its influence on autonomic signaling pathways.

Influence on Emetic and Histaminic Pathways

The drug's mechanism extends to the Chemoreceptor Trigger Zone (CTZ), where it blocks D2 receptors, and includes antagonism of H1 histamine receptors. These actions inhibit the afferent signaling that triggers the emetic center, and further influences systemic physiology by engaging alternative signaling systems.

Dosage and Administration Information

Neuroleptil (pericyazine) is approved for oral administration and is available in forms such as tablets (e.g., 2.5 mg, 10 mg) and oral solutions or drops. The correct use of this medicine is based on a structured dosing schedule and administration guidelines.


Official Dosing and Titration

Dosing requirements are highly individualized and are typically initiated at a low dose, then progressively increased until the optimal effect is achieved. After this phase, the dose is adjusted downwards to the minimum required for maintenance. The maximum recommended daily dose for adults with severe conditions is 300 mg.

Adult Indication Initial Dosing Schedule (Daily) Maximum Dose
Severe Conditions 75 mg in divided doses; increase by 25 mg weekly 300 mg
Mild/Moderate Conditions 15 mg to 30 mg in two divided doses Not specified; use lowest effective dose

Administration Requirements

  • Dose Timing: The total daily dose is split into portions, often with a larger dose given in the evening to align with the medicine's properties.
  • Tablet Intake: Tablets should be swallowed whole with water while sitting or standing. Patients are advised not to handle the tablets for longer than necessary to prevent contact skin sensitization.
  • Antacid Separation: Neuroleptil should be taken at least two hours apart from antacids, if possible, to avoid interference with absorption.

Use in Specific Populations

  • Older Adults (Geriatric): Initial doses are significantly lower, typically starting at 15 mg to 30 mg daily, or even 5 mg to 10 mg for mild conditions, with the maintenance dose potentially being half to a quarter of the standard adult dose.
  • Pediatric: The tablets are generally not recommended for children. Use in children under one year of age is contraindicated.
  • Discontinuation: The dosage must be gradually reduced under supervision; abrupt cessation of therapy is strongly discouraged.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neuroleptil


Evidence for Use in Schizophrenia and Psychotic Illnesses

Research has explored the use of this medication in adults who have been diagnosed with schizophrenia and other psychotic illnesses. Studies were primarily conducted as short-term randomized controlled trials (RCTs), where researchers monitored groups of participants over a defined time interval. These trials were applied in research contexts involving fluctuating or unstable symptoms and research examined how symptoms evolved in the observed populations. Outcomes related to symptom intensity, variability, and changes in the severity of these conditions were the primary focus of these research efforts.

Studies report patterns observed related to outcomes capturing phases of heightened symptom activity, which were typically documented over observation periods of several weeks. Research describes changes measured during the study period concerning symptoms like thought disorder and perception changes. However, evidence is limited regarding sustained effects over many years. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.


Evidence for Controlling Hostility, Impulsiveness, and Aggressiveness

Research explored the medication's use in individuals whose conditions were characterized by behaviors such as hostility, impulsiveness, and aggressiveness. Studies explored the monitoring of these types of symptom patterns through short-term trials. The research examined the use of the drug in observational settings evaluating daily-life functioning in participants whose conditions were marked by functional limitations due to these behaviors.

Studies monitored changes measured on aggression and agitation scales over the defined time intervals of the trials. The research describes how outcomes reflecting daily functioning or activity level were measured and reported in the specific study populations. Findings helped contextualize how patients reported their experience during periods of increased symptom activity.


Long-Term Studies and Follow-Up Data

Studies exploring the use of this medication have largely focused on short-term outcomes, meaning that the long-term effects are not fully established. Research provides insight into short-term changes, but the evidence for what happens after many years of evaluation is limited.

Some extended-duration data are available from follow-up or open-label extension studies, which describe patterns related to outcomes related to systemic or functional imbalance over slightly longer periods. However, these extension phases often involve participants who have already been observed in the earlier trials, which means results apply only to the populations studied and may not reflect general long-term patterns.


Evidence in Special Populations

The medication was evaluated in specific special populations, particularly children over the age of five years whose conditions were characterized by severe behavioral patterns. Research for this group has explored outcomes related to physical discomfort and behavioral changes, but evidence quality varies across studies and is generally limited.

For older adults (geriatric population), studies monitored responses over defined time intervals but often included only small numbers of participants. Research descriptions for these groups highlight that subgroup findings are uncertain due to limited evidence.


What is Still Uncertain About Neuroleptil Research

Research so far indicates several areas where additional information and further study are needed. Sample sizes were modest in many of the trials, meaning the findings describe group patterns, not personal outcomes, and may not fully represent the diversity of individuals using the medication. Evidence is limited regarding the use in patients with severe underlying physical conditions, as these groups were often excluded from the main trials.

Furthermore, comparative evidence is lacking in the research explored for certain scenarios. The research highlights what is known — and what is still uncertain — about how symptoms may evolve in different individuals.

Key Studies & References

  1. Neulactil 2.5 mg tablets - NEW ZEALAND DATA SHEET
  2. Deprescribing Inappropriate Pericyazine (DIP) in Adults in Primary Care: Guidance Summary (NHS)

Frequently Asked Questions (FAQ)

Common questions about Neuroleptil (FAQ)


Q: How quickly should I expect Neuroleptil to start working?

While some effects like sedation may be felt soon after administration, regulatory documents suggest that the full calming and stabilizing effects often require several days of treatment to manifest as the body adjusts to the medication.


Q: Can Neuroleptil cause weight gain?

Regulatory documents suggest this medication carries a moderate risk of causing weight gain. Like many medications in its class, it may also be linked to other metabolic changes, such as increased prolactin levels.


Q: Are there withdrawal symptoms when stopping Neuroleptil?

Official warnings strongly advise against stopping this medication suddenly. Abrupt discontinuation can be associated with withdrawal symptoms, which may include physical reactions such as nausea, vomiting, anxiety, restlessness, and movement difficulties. Changes to the dosage should only be made gradually and under the direction of a healthcare professional.


Q: Is Neuroleptil used for anxiety or just psychosis?

Neuroleptil is officially classified as a major tranquilizer (neuroleptic). Its therapeutic purpose, according to official product information, includes helping to alleviate profound anxiety and states of severe emotional unease, in addition to managing symptoms associated with psychotic illnesses.


Q: Can Neuroleptil cause tremor or involuntary movements?

Yes, the medication is known to cause extrapyramidal symptoms, which are movement-related side effects. These can manifest as physical reactions like muscle stiffness, difficulty moving, and involuntary movements, including a noticeable tremor.


Q: Does Neuroleptil interact with herbal supplements like St. John's Wort?

While specific interactions may vary, regulatory information indicates that caution is necessary with any substance that affects the central nervous system or liver enzymes. Official product information suggests that the use of any supplements, including St. John's Wort, should be discussed with a healthcare professional.


Q: How long does the effect of a Neuroleptil tablet last?

The exact duration of a single dose is not specified in regulatory documents. However, the official dosing schedule often involves splitting the total daily dose, frequently with a larger portion given in the evening. This regimen is consistent with the need to maintain a stabilizing effect over an extended period, often throughout the night.


Q: Are there any known severe or rare side effects of Neuroleptil?

Yes, official product information highlights the risk of several rare but serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), which is marked by fever and muscle stiffness, Tardive Dyskinesia (involuntary, repetitive movements), and cardiovascular risks like QT interval prolongation (a dangerous heart rhythm disturbance).


Q: Does Neuroleptil require regular blood tests?

According to official safety information, blood monitoring is required for patients using this medicine. This is specifically necessary to monitor for and detect very rare, but serious, conditions like agranulocytosis, which is a severe drop in the white blood cell count.


Q: What happens if I miss a dose of Neuroleptil?

Regulatory patient information generally provides guidance for missed doses. For many prescription medicines, the general recommendation is to check with a healthcare professional or pharmacist, as instructions can vary based on the schedule. Patients are consistently advised never to take a double dose to compensate for a missed one.


Q: Is Neuroleptil the same as other 'major tranquilizers'?

Neuroleptil is formally classified as a neuroleptic drug, a term often used interchangeably with major tranquilizer. It specifically belongs to the phenothiazine derivative family of chemical compounds. While it shares the general purpose of calming and stabilizing emotional states with others in its class, its specific effects are unique to the substance periciazine.


Q: How does Neuroleptil affect the brain's dopamine levels?

The mechanism of action described in official regulatory texts is that the drug acts as a multi-receptor antagonist. Its primary action is by blocking activity at D2 dopamine receptors in the central nervous system. By blocking these receptors, the medication helps to dampen excessive dopaminergic signaling in the brain.


Q: Does Neuroleptil show up on standard drug tests?

Since Neuroleptil is a phenothiazine derivative, which is a class of medication, regulatory data indicates that it may potentially cause a false positive result on some drug screening tests designed to detect this class of substance.


Q: Why do some people feel restless when they first start Neuroleptil?

The official product information mentions extrapyramidal symptoms as possible adverse reactions. A specific type of movement disorder called akathisia—an inner feeling of restlessness and the compelling need to move—is a known side effect associated with the use of neuroleptic medications.


Q: Is Neuroleptil used in children?

Official documents state that the tablets are generally not recommended for children. However, the use of the oral solution formulation may be considered for children over the age of five years who are experiencing conditions characterized by severe behavioral patterns.


Q: Are there any reports of Neuroleptil causing vision problems?

Yes, regulatory documents mention that the medication can cause anticholinergic effects, such as blurred vision. There are also rarer reports in the safety information of the potential for pigmentary retinopathy (retinal changes) and the risk of developing angle-closure glaucoma.


Q: How is Neuroleptil stored?

Official patient information requires that the medicine be stored in its original packaging, protected from light, and kept at a temperature below 30 C. The product information states the medicine must be stored out of the sight and reach of children.

How should Neuroleptil be stored and disposed of?

How to Store and Dispose of Neuroleptil (Pericyazine)

The storage of Neuroleptil is strictly governed by regulatory requirements to ensure product stability. The medicine, particularly tablets, must be stored at a temperature below 30 C and should be protected from light.


Storage Requirements

  • Keep the medicine in its original package and outer carton.
  • It is mandatory to store the product out of the sight and reach of children.
  • For the oral syrup formulation, any unused medicine must be discarded one month after opening the bottle.

Disposal

To dispose of unused or expired Neuroleptil, patients should follow official guidelines. The preferred method is to return the medicine to a pharmacy or a designated drug take-back program. Pericyazine must not be disposed of via wastewater (flushed down the toilet) or mixed with household trash unless specific preparation steps are followed when a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neuroleptil found in:

A-Z Index: